BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 06, 2004
 |  BioCentury  |  Emerging Company Profile

Novexel: Broad spectrum spinout

Novexel S.A., which spun out of sanofi-aventis SA last week, will seek to capitalize on an anti-infectives pipeline and capabilities inherited from the Aventis side of the pharma merger. In addition to infrastructure and experienced personnel, the company has two compounds in Phase I trials and about 18 projects in earlier stages of R&D.

"There's no particular technology per se here," said CEO Iain Buchanan. "The assets are purely target- and compound-based."

The company expects each of its clinical compounds to offer improvements over marketed drugs in their respective classes. Novexel's most advanced compound is NXL-201, an echinocandin that inhibits beta 1,3-D-glucan synthase, blocking production of beta 1,3-D-glucan, a major component of fungal cell walls.

Novexel said NXL-201 may have an advantage over Cancidas caspofungin, a marketed echinocandin from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.), because NXL-201's tolerability and safety profile allow for...

Read the full 728 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >